Clinical trial

A Post-authorisation/Post-marketing Observational Study to Evaluate the Association Between Exposure to AZD1222 and Safety Concerns Using Existing Secondary Health Data Sources

Name
D8111R00006
Description
A study based on electronic heath records will evaluate the incidence and relative risk of safety concerns and adverse events of special interest (AESIs) following immunisation by AZD1222 in the real-world setting. A cohort and a self-controlled case series desings will be used.
Trial arms
Trial start
2022-02-18
Estimated PCD
2024-01-24
Trial end
2024-01-24
Status
Completed
Treatment
AZD1222
Covid-19 AstraZeneca Vaccine
Arms:
AZD1222
Size
5321930
Primary endpoint
Adverse events of special interest
up to 365 days
Eligibility criteria
Inclusion criteria for AZD1222, unvaccinated, and active comparators\*: * Have at least 12 months of data available before the index date * Have no record of vaccination with any other COVID-19 vaccine on or before the index date Inclusion criteria for historical comparators: - Have at least 12 months of data available before the index date Exclusion criteria: For each AESI, subjects (in any matched cohort) who had a specific AESI during the look-back period before the index date will be excluded from the cohort for the analysis of that specific AESI, but not from the cohorts for analysis of other AESIs. - If a subject had a specific AESI between the index date and the start of the risk window or had any censoring criteria within this time period, the subject will be excluded from the analysis of that specific AESI. \*Feasibility of the active comparator analysis will be assessed prior to conducting the analysis to ensure comparability between groups
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 5321930, 'type': 'ACTUAL'}}
Updated at
2024-02-21

1 organization

1 product

2 indications

Organization
AstraZeneca
Product
AZD1222
Indication
COVID-19